- Home
- URGN vs AMN Comparison
URGN vs AMN Comparison
Compare URGN & AMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- AMN
- Stock Information
- Founded
- URGN 2004
- AMN 1985
- Country
- URGN United States
- AMN United States
- Employees
- URGN N/A
- AMN N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- AMN Assisted Living Services
- Sector
- URGN Health Care
- AMN Health Care
- Exchange
- URGN Nasdaq
- AMN Nasdaq
- Market Cap
- URGN 831.6M
- AMN 840.0M
- IPO Year
- URGN 2017
- AMN 2001
- Fundamental
- Price
- URGN $19.22
- AMN $18.62
- Analyst Decision
- URGN Strong Buy
- AMN Hold
- Analyst Count
- URGN 8
- AMN 8
- Target Price
- URGN $29.00
- AMN $31.92
- AVG Volume (30 Days)
- URGN 1.3M
- AMN 664.2K
- Earning Date
- URGN 08-07-2025
- AMN 08-07-2025
- Dividend Yield
- URGN N/A
- AMN N/A
- EPS Growth
- URGN N/A
- AMN N/A
- EPS
- URGN N/A
- AMN N/A
- Revenue
- URGN $91,871,000.00
- AMN $2,852,436,000.00
- Revenue This Year
- URGN $39.80
- AMN N/A
- Revenue Next Year
- URGN $108.94
- AMN $1.83
- P/E Ratio
- URGN N/A
- AMN N/A
- Revenue Growth
- URGN 8.98
- AMN N/A
- 52 Week Low
- URGN $3.42
- AMN $17.45
- 52 Week High
- URGN $19.69
- AMN $70.07
- Technical
- Relative Strength Index (RSI)
- URGN 76.29
- AMN 37.99
- Support Level
- URGN $18.37
- AMN $19.47
- Resistance Level
- URGN $19.36
- AMN $20.13
- Average True Range (ATR)
- URGN 1.03
- AMN 0.90
- MACD
- URGN 0.25
- AMN -0.13
- Stochastic Oscillator
- URGN 91.26
- AMN 5.44
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About AMN AMN Healthcare Services Inc
AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are; nurse and allied solutions, physician and leadership solutions, and technology and workforce solutions. A majority of its revenue is generated from the nurse and allied solutions segment which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.